The major goals of this Core Facility, which was renovated by the University of Arizona specifically for this Program Project Grant are to synthesize, purify and analyze 200 mg to 5 g quantities of biologically active peptides that are needed for extensive biochemcal, pharmacological, biophysical and biological studies, and for toxicological studies which are part of this Program Project Grant. Of importance will be the development of proper synthetic, purificaiton and analytical methodologies for preparation of peptides for the extensive biological and toxicology studies needed if one is eventially apply for clinical trials with the FDA.
The Specific Aims of the Core Facility are: 1) To prepare 1g to 10g quantities of the following ligands: a) c[D-Pen2,D-Pen5] enkephalin (DPDPE); b) biphalin; c) c[Phe(pCl)4]DPDPE; d) deltorphin II; e) [Cys4]deltorphin and perhaps other potent an selective compounds. For a) and b) to also establish a """"""""gold standard"""""""" for preclinical studies and clinical trials. 2) to establish and develop all necessary analytical methods, purification protocol, and synthetic methods that are needed for preparing ligands for the various needs of all investigators in the Program Project and that are acceptable to the FDA. 3) To prepare by asymmertic synthesis and other synthetic methods the necessary amino acids needed for the preparation of ligands for the Program Project. 4) to prepare up to gram quantities of highly potent peptides, peptidomimetics, peptide conjugates that are needed for further biological of biophysical studies. These include [Phe(pCl)4.4]biphalin, Tyr-D-Pen-Gly-Phe-Cys-Ser(O-Gluc)-Gly, and lipid-deltorphin conjugates. 5) To prepare other peptides or peptidomimetic ligands that are discovered, and that are needed by investigators in the Program Project Grant for further biological or biophysical studies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA006284-10
Application #
6104012
Study Section
Project Start
1999-04-01
Project End
2000-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
10
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Remesic, Michael; Macedonio, Giorgia; Mollica, Adriano et al. (2018) Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors. Bioorg Med Chem 26:3664-3667
Mowlazadeh Haghighi, Saghar; Zhou, Yang; Dai, Jixun et al. (2018) Replacement of Arg with Nle and modified D-Phe in the core sequence of MSHs, Ac-His-D-Phe-Arg-Trp-NH2, leads to hMC1R selectivity and pigmentation. Eur J Med Chem 151:815-823
Sandweiss, A J; McIntosh, M I; Moutal, A et al. (2018) Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential. Mol Psychiatry 23:1745-1755
Bannister, Kirsty; Qu, Chaoling; Navratilova, Edita et al. (2017) Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain 158:2386-2395
Vardanyan, Ruben S; Cain, James P; Haghighi, Saghar Mowlazadeh et al. (2017) Synthesis and Investigation of Mixed ?-Opioid and ?-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain. J Heterocycl Chem 54:1228-1235
Cai, Minying; Marelli, Udaya Kiran; Mertz, Blake et al. (2017) Structural Insights into Selective Ligand-Receptor Interactions Leading to Receptor Inactivation Utilizing Selective Melanocortin 3 Receptor Antagonists. Biochemistry 56:4201-4209
Remesic, Michael; Lee, Yeon Sun; Hruby, Victor J (2016) Cyclic Opioid Peptides. Curr Med Chem 23:1288-303
Ramos-Colon, Cyf N; Lee, Yeon Sun; Remesic, Michael et al. (2016) Structure-Activity Relationships of [des-Arg7]Dynorphin A Analogues at the ? Opioid Receptor. J Med Chem 59:10291-10298
Hall, Sara M; Lee, Yeon Sun; Hruby, Victor J (2016) Dynorphin A analogs for the treatment of chronic neuropathic pain. Future Med Chem 8:165-77
Deekonda, Srinivas; Cole, Jacob; Sunna, Sydney et al. (2016) Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations. Bioorg Med Chem Lett 26:222-7

Showing the most recent 10 out of 268 publications